January 3, 2018 / 1:37 PM / in 4 minutes BRIEF-Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder Reuters Staff 1 Min Read 
Jan 3 (Reuters) - Vistagen Therapeutics Inc: 
* VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AV-101 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER 
* VISTAGEN THERAPEUTICS INC - ‍ON TRACK TO DOSE FIRST PATIENT IN AV-101 PHASE 2 MDD ADJUNCTIVE TREATMENT STUDY IN Q1 OF 2018​ Source text for Eikon: Further company coverage: